Phase 2 N=133 Treatment of High-Grade Pre-Neoplastic Cervical Lesions (CIN 2/3)
Cervical Intraepithelial Neoplasia · Cervical Dysplasia
Primary: Incidence of Objective Response — 32; 36; 30; 0 Participants — p=0.043
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=5,759 Cervical Intraepithelial Neoplasm (CIN)-Warts Efficacy Trial in Women (Gardasil)(V501-013)(COMPLETED)
Cervical Cancer · Genital Warts
Primary: Incidence of HPV 6/11/16/18-related Cervical Intraepithelial Neoplasia (CIN)(Any Grade), Adenocarcinoma In Situ (AIS) or Cervical Cancer — 0; 1.2 incidence rate per 100…
Phase 1 N=30 Intravaginal Artesunate for the Treatment of HPV+ High Grade Cervical Intraepithelial Neoplasia (CIN2/3)
Cervical Intraepithelial Neoplasia Grade 2/3 · High-risk HPV (Any Strain)
Primary: Number of Participants With Serious Adverse Events — 0; 0; 0; 0 Participants
N/A N=400 Cryotherapy vs. LEEP to Treat Cervical Intraepithelial Neoplasia (CIN) 2/3 Among HIV-positive Women
Cervical Intraepithelial Neoplasia
Primary: Recurrence of Cervical Intraepithelial Neoplasia Among HIV-positive Women — 60; 37 Participants
Phase 2 N=130 Celecoxib in Treating Patients With Cervical Intraepithelial Neoplasia
Cervical Carcinoma · Cervical Intraepithelial Neoplasia Grade 2/3 · Stage 0 Cervical Cancer
Primary: Histologic Regression — 40; 34.1 percentage of participants
Early Phase 1 N=13 Topical Fluorouracil and Imiquimod in Treating Patients With High-Grade Cervical Intraepithelial Neoplasia
Cervical Intraepithelial Neoplasia Grade 2/3 · Cervical Squamous Cell Carcinoma In Situ · Cervical Squamous Intraepithelial Neoplasia 2
Primary: Feasibility of Intravaginal Use 5-FU and Imiquimod on Alternating Weeks in Women With Biopsy Confirmed High Grade Cervical Squamous Intraepithelial Lesions. — 4; 1…
Phase 3 N=12,167 Cervical Intraepithelial Neoplasm (CIN) in Women (Gardasil) (V501-015)
Cervical Cancer · Genital Warts
Primary: Incidence of the Composite Endpoint of Human Papillomavirus (HPV) 16/18-related Cervical Intraepithelial Neoplasia (CIN) 2 or Worse in the Base Study — 0.0; 0.4…
N/A N=2,661 Optimal Strategy for the Management of ASCUS Cytology in Health Care Services of Medellin, Colombia
Cervical Abnormalities · Cervical Intraepithelial Neoplasia Grade 2/3 · Cervical Cancer
Primary: Cumulative Number of Participants Diagnosed by the Community Pathologist With Cervical Intraepithelial Neoplasia Grade 2 or Higher (CIN2+): "Community-based CIN2+"…
Phase 1 N=39 Therapeutic Vaccination for Patients With HPV16+ Cervical Intraepithelial Neoplasia (CIN2/3)
HPV16 Positive · Cervical Intraepithelial Neoplasia (CIN 2/3)
Primary: Number of Participants With Related Serious Adverse Events — 0; 0; 0; 0 Participants
Phase 3 N=203 REVEAL 2 Trial (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)
Cervical Dysplasia · Cervical High Grade Squamous Intraepithelial Lesion · HSIL
Primary: Baseline Biomarker-positive Participants for ITT Population: Percentage of Participants With No Histologic Evidence of Cervical HSIL on Histology Sample and No Evidence…
N/A N=467 HPV Test-and-Treat-Strategy Versus Cytology-based Strategy for Prevention of CIN2+ in HIV-Infected Women
HIV-1 Infection
Primary: Cumulative Rate of Cervical Intraepithelial Neoplasia (CIN2+) (CIN2, CIN3 or Invasive Cancer) by Week 130 — 24.9; 26.5 Events per 100 persons
Phase 2 N=147 Safety and Efficacy of A-007 Topical Gel in the Treatment of High-Grade Squamous Intraepithelial Lesions (HSIL) of the Cervix
Cervical Intraepithelial Neoplasia · Uterine Cervical Dysplasia
Primary: Pathological Response — 20; 24 participants
N/A N=47,208 Evaluation of the Cobas® 4800 HPV Test for the Detection of High-grade Cervical Disease
Human Papilloma Virus (HPV)
Primary: Percentage of Participants With a Diagnosis of ≥ CIN2 — 14.0; 0.8 Percentage of participants
N/A N=9 Use of High-Resolution Microendoscopy (HRME) in Patients With Adenocarcinoma In-Situ (AIS) of the Cervix
Cervix Carcinoma
Primary: Feasibility of Acquiring In-vivo High-Resolution Microendoscopy (HRME) Images of Cervix Prior to Conization
Phase 2 N=262 Dose-finding Study of Hexaminolevulinate (HAL) Photodynamic Therapy (PDT) to Treat Cervical Neoplasia
Cervical Intraepithelial Neoplasia
Primary: Comparison of Lesion Response Rates of Three Different Doses of HAL PDT and Placebo at 3 Months After Treatment. — 95; 69; 63; 57 percentage of patients
Phase 2 N=81 A Clinical Trial of PepCan to Two Therapy Arms for Treating Cervical High-Grade Squamous Intraepithelial Lesions
Cervical Intraepithelial Neoplasia
Primary: Number of Subjects With Complete Response With the Intention-to-treat (ITT) Analysis — 12; 20 Participants
Phase 2 N=70 Treatment of Anal High-grade Squamous Intraepithelial Lesions (HSIL) Through Use of a Chinese Herbal Topical Cream
Anus Neoplasms
Primary: Final Response of Anal High-grade Squamous Intraepithelial Lesions (HSIL) — 3; 0; 7; 3 participants — p=.042
Phase 3 N=201 REVEAL 1 (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)
Cervical Dysplasia · Cervical High Grade Squamous Intraepithelial Lesion · HSIL
Primary: Percentage of Participants With No Evidence of Cervical HSIL on Histology and No Evidence of HPV-16 and/or HPV-18 in Cervical Samples — 22.5; 11.1 percentage of…
N/A N=45 Coherence Imaging of the Cervical Epithelium With Scanning a/LCI
Cervical Dysplasia
Primary: Sensitivity of Scanning a/LCI Probe to Detect Cervical Dysplasia as Measured by Percentage of Correctly Identified Positive Biopsies — 90.3; 100.0 percentage of correct…
N/A N=55 Coherence Imaging of the Cervical Epithelium
Cervical Epithelia
Primary: Number of Patients With Interferometric Data Acquired From Cervical Epithelium — 3; 41 patients
Phase 2 N=16 Vaccine Therapy in Preventing Cervical Cancer in Patients With Cervical Intraepithelial Neoplasia
Cervical Cancer · Precancerous Condition
Primary: Safety and Toxicity — 0; 0; 0 Participants
N/A N=1,132 An Innovative Treatment for Cervical Precancer (UH3)
Cervical Intraepithelial Neoplasia
Primary: Proportion of Participants With Residual CIN2+ — 18; 29; 25 Participants
Phase 2 N=98 Green Tea Extract in Preventing Cervical Cancer in Patients With Human Papillomavirus and Low-Grade Cervical Intraepithelial Neoplasia
Cervical Cancer · Cervical Intraepithelial Neoplasia Grade 1 · Human Papilloma Virus Infection
Primary: Complete Response - Clearance of Oncogenic Human Papillomavirus (HPV) and Complete Colposcopic, Histologic and Cytologic Clearance of Disease — 7; 6 participants
Phase 2 N=33 Cidofovir in Treating HIV-Infected Patients With High-Grade Squamous Intraepithelial Lesions of the Skin Near the Anus
Anal Cancer · Precancerous Condition
Primary: Proportion of Patients With Regression of Perianal High-grade Squamous Intraepithelial Lesions (HSIL) — 0.515 proportion of participants
Phase 3 N=5,060 Randomized Clinical Trial on Clinical Management of ASCUS and LSIL (ALTS)
Cervical Intraepithelial Neoplasia
Primary: Percentage of Participants With Cervical Intraepithelial Neoplasia III (CIN III) — 10.93; 10.25; 10.84 percentage of participants
N/A N=737 Adequacy and Efficacy of the e2TM Cervical Cell Collector Compared to Standard Spatula/CytoBrush Technique.
Colposcopy · Biopsy
Primary: Cell Collection Efficacy — 174; 170; 33; 14 Participants
Phase 2 N=10 A Study of INO-3112 DNA Vaccine With Electroporation in Participants With Cervical Cancer
Cervical Cancer
Primary: Percentage of Participants With at Least 1 Treatment Emergent Adverse Event (TEAE) — 100; 100 percentage of participants
Phase 3 N=1,025 Phase 3 Trial of a Bivalent Human Papilloma Virus (HPV) Vaccine (Cecolin®) in Young Girls
Cervical Cancer
Primary: Geometric Mean Concentration (GMC) of Anti-HPV-16 Immunoglobulin G (IgG) Antibodies One Month After the Second Dose — 1507.4; 2408.7; 3326.1; 1352.4 IU/mL
Phase 2 N=50 A Study of AGEN2034 in Advanced Tumors and Cervical Cancer
Advanced Cancer · Cervical Cancer
Primary: Phase 1: Number of Participants Experiencing Dose-limiting Toxicities (DLTs) for Balstilimab — 0; 0; 0; 0 Participants
Phase 2 N=33 Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3)
Vulvar High Grade Squamous Intraepithelial Lesion (HSIL) · Vulvar Dysplasia · Vulvar Intraepithelial Neoplasia (VIN)
Primary: Percentage of Participants With No Histologic Evidence of Vulvar HSIL and No Evidence of HPV-16 and/or HPV-18 in Vulvar Tissue Samples — 15.0; 37.5 percentage of…